A composition for use in preventing one or more cardiac channelopathies, preferably wherein the composition is adapted for parenteral or oral administration, conditions resulting from irregularities or alterations in cardiac patterns, or both in a human or animal subject comprising: one or more pharmacologically active agents selected from one or more drug classes comprising β-blockers, sodium channel blockers, potassium supplements, potassium channel openers, hERG current enhancers, calcium channel blockers, agents for correcting trafficking defects, gap junction coupling enhancers, or any combinations thereof; one or more empty liposomes for administration concomitantly with administration of the pharmacologically active agent; and a pharmaceutically acceptable dispersion medium or vehicle, wherein the active agent, the empty liposome or both are dispersed, or suspended in the medium or the vehicle, wherein the agents are selected from Aloxi or palonasitron HCL, Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine-Chlorpheniramine, Chlorpromazine, Cisapride, Celexa, Clarithromycin, Erythromycin, Curcumin, Disopyramide, Dofetilide, Domperidone, Dronedarone, Droperidol, Grepafloxacin, Haldol, Haloperidol, Halofantrine, Ibutilide, Levomethadyl, Lidoflazine, Loratidine, Lovostatin, Mesoridazone, Methadone, Methanesulphonanilide (E-4031), Moxifloxacin, Pentamadine, Pimozide, Prenylamine, Probucol, Procainamide, Propafenone, Pyrilamine, Quinidine- Terfenidine, Sertindole, Sotalol, Sparfloxacin, and Thioridazine, wherein the cardiac channelopathy or the condition resulting from the irregularity or alteration in the cardiac pattern is selected from the group consisting of long QT syndrome (LQTS), atrial flutter, atrial fibrillation, ventricular tachycardia, sinus bradycardia, sinus tachycardia, atrial tachycardia, atrial fibrillation, atrial flutter, atrioventricular nodal block, atrioventricular node reentry tachycardia, atrioventricular reciprocating tachycardia, ventricular tachycardia, ventricular fibrillation, or any combination thereof. one or more pharmacologically active agents selected from one or more drug classes comprising β-blockers, sodium channel blockers, potassium supplements, potassium channel openers, hERG current enhancers, calcium channel blockers, agents for correcting trafficking defects, gap junction coupling enhancers, or any combinations thereof; one or more empty liposomes for administration concomitantly with administration of the pharmacologically active agent; and a pharmaceutically acceptable dispersion medium or vehicle, wherein the active agent, the empty liposome or both are dispersed, or suspended in the medium or the vehicle, wherein the agents are selected from Aloxi or palonasitron HCL, Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine-Chlorpheniramine, Chlorpromazine, Cisapride, Celexa, Clarithromycin, Erythromycin, Curcumin, Disopyramide, Dofetilide, Domperidone, Dronedarone, Droperidol, Grepafloxacin, Haldol, Haloperidol, Halofantrine, Ibutilide, Levomethadyl, Lidoflazine, Loratidine, Lovostatin, Mesoridazone, Methadone, Methanesulphonanilide (E-4031), Moxifloxacin, Pentamadine, Pimozide, Prenylamine, Probucol, Procainamide, Propafenone, Pyrilamine, Quinidine- Terfenidine, Sertindole, Sotalol, Sparfloxacin, and Thioridazine, wherein the cardiac channelopathy or the condition resulting from the irregularity or alteration in the cardiac pattern is selected from the group consisting of long QT syndrome (LQTS), atrial flutter, atrial fibrillation, ventricular tachycardia, sinus bradycardia, sinus tachycardia, atrial tachycardia, atrial fibrillation, atrial flutter, atrioventricular nodal block, atrioventricular node reentry tachycardia, atrioventricular reciprocating tachycardia, ventricular tachycardia, ventricular fibrillation, or any combination thereof. <EOS>